$7.31+0.01 (+0.14%)
At close: Oct 2, 2026, 4:00 PM ET
Grifols SA · Overview
Industry: Drugs · see every company filed here →
Grifols SA scores 50/100. Mixed. Strongest on value, financial health is the soft spot, trading at 8× earnings versus 400 Healthcare peers.
Tenet Score · vs sector
n=400Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value97
Quality46
Health29
Growth30
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
ValueAQualityDHealthFGrowthDMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
8.2×
price ÷ the latest fiscal year EPS
P/B
—
no P/B on file
P/S
0.6×
price to sales
ROE
—
negative equity denominator
Operating margin
16.5%
before interest and tax
Net margin
6.7%
fiscal 2025
Current ratio
2.51
fiscal 2025
Net debt / EBITDA
—
debt data unavailable
EPS CAGR 5y
−0.3%
trailing 5-year, per share
Market cap
$5.0B
mid cap
Div yield
3.86%
fiscal-year dividend ÷ price
52-wk range
6.96 – 10.23
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
0 / 17
- ✕ Buffett Quality
- ~ Piotroski F-Score
- ✕ Munger Compounders
- ~ Magic Formula
- ~ Graham Defensive
- ✕ Income & Dividend Safety
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
TBA
next reportBeat/miss history appears here after the first tracked report.Statistics
ROIC13%
Gross margin38%
Technical Analysis
Downtrend short-term signalvs 50-day−5.5%
vs 200-day−10.6%
RSI (14)41
News & Insights
Headlines are on the News tab.Dividends
3.86% yield
Pays 3.86%. Yield is one component of total return.
Ownership
21% institutional
13F flows & insider trades land here.
About Grifols SA
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division resea…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold GRFS, and at what weight. Everything else on this page stays open.Create a free account